Consulting firm fined for opioid promotion, highlighting dangers of marketing mistakes in pharmaceutical industry.
-
Consulting firm McKinsey fined $230 million for US opioid settlements • 0:06
-
Involvement in promotion and marketing of OxyContin led to the fine • 0:25
-
FDA hearing discussed issues related to OxyContin at the time • 0:33
-
Documentary series ‘Painkiller’ on Netflix provides insights into the opioid crisis • 1:27
-
Warning about potential cancer explosion and autoimmunity concerns • 1:54
-
Emphasis on understanding mechanisms like Faron, p53, and SV40 • 2:01
-
Importance of approaching medical research and interventions cautiously • 3:04
Marketing strategy of OxyContin leading to addiction crisis and legal consequences.
-
Purdue Pharma settled for $230 million due to deceptive marketing of OxyContin. • 4:02
-
OxyContin was aggressively promoted between 1996 and 2001, leading to widespread abuse. • 4:40
-
FDA regulatory oversight was circumvented, allowing OxyContin to be marketed unchecked. • 5:11
-
Sales of OxyContin grew significantly due to marketing efforts and aggressive promotion. • 6:53
-
Aggressive marketing tactics included targeting prescribers and offering incentives. • 7:13
-
OxyContin became a leading drug of abuse in the United States by 2004. • 7:56
-
Purdue Pharma’s strategy involved identifying and promoting to prescribers already prescribing opioids. • 8:14
Comparison between Covid vaccines and Oxycontin marketing, highlighting conflicts of interest and lack of targeted approach in vaccine distribution.
-
Sophisticated marketing campaign led to significant drug addictions with Oxycontin. • 8:39
-
Governments promoted vaccines, but misinformation about transmission and pandemic control was not challenged. • 9:05
-
Conflict of interest highlighted with FDA officials transitioning to pharmaceutical industry, raising concerns about regulatory decisions. • 10:04
-
Issue with widespread vaccine rollout instead of targeted approach for high-risk populations. • 12:05
Lessons on the risks of misrepresenting addiction and adverse events in marketing pharmaceuticals.
-
Misrepresentation of addiction risk in pharmaceutical marketing can have severe consequences. • 12:24
-
Companies may downplay risks to certain patient cohorts, leading to adverse events. • 12:35
-
Ongoing issues with misrepresentation of risks in pharmaceutical industry globally. • 12:52
-
Purdue Pharma misrepresented addiction risk of OxyContin, leading to legal consequences. • 13:00
-
Purdue Pharma faced criminal charges and fines for misbranding OxyContin. • 14:59
-
Lessons learned on potential corruption and financial influence in pharmaceutical decision-making. • 16:11
Lessons from past regulatory failure in applying therapies broadly, focusing on high-risk populations, and potential consequences of political influence and financial gain in the Covid-19 pandemic.
-
Regulatory failure due to one person’s influence and financial gain led to a major error affecting over 800,000 people in the US. • 16:55
-
Applying therapies broadly without thorough understanding of the disease can be dangerous. • 17:47
-
Focusing on high-risk populations is crucial to avoid risks associated with not treating or intervening. • 18:05
-
Political influence and financial gain may have impacted the handling of the pandemic, leading to localized epidemics in highly vaccinated regions. • 18:32
-
Africa’s approach with limited resources in managing the pandemic can provide valuable lessons. • 19:07
-
Lessons from the pandemic may come at a significant cost and be painful. • 19:16